Century Therapeutics, Inc.
IPSC
$2.45
$0.156.30%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | 12,667.72% | 1,457.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | 12,667.72% | 1,457.09% |
| Cost of Revenue | -32.95% | -17.27% | -1.33% | 13.49% | 31.75% |
| Gross Profit | 21.85% | 14.79% | -1.55% | 465.97% | -14.41% |
| SG&A Expenses | -26.56% | -18.16% | -6.03% | -3.83% | -6.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.59% | -17.48% | -2.43% | 8.78% | 21.01% |
| Operating Income | 22.99% | 15.60% | 0.26% | 336.92% | -8.44% |
| Income Before Tax | 43.90% | -10.21% | -4.35% | 372.83% | 14.83% |
| Income Tax Expenses | -103.83% | -- | -- | -- | 304.37% |
| Earnings from Continuing Operations | 46.85% | -10.24% | -4.27% | 372.82% | 8.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.85% | -10.24% | -4.27% | 372.82% | 8.44% |
| EBIT | 22.99% | 15.60% | 0.26% | 336.92% | -8.44% |
| EBITDA | 26.32% | 16.70% | -0.54% | 375.60% | -10.42% |
| EPS Basic | 48.00% | -8.00% | 0.74% | 297.56% | 35.69% |
| Normalized Basic EPS | 21.75% | 13.28% | 0.67% | 297.62% | 21.73% |
| EPS Diluted | 48.50% | -8.11% | 0.03% | 297.56% | 35.07% |
| Normalized Diluted EPS | 21.75% | 13.28% | 0.67% | 297.44% | 21.73% |
| Average Basic Shares Outstanding | 2.19% | 2.08% | 5.05% | 38.08% | 42.37% |
| Average Diluted Shares Outstanding | 2.19% | 2.08% | 5.05% | 38.21% | 42.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |